NEW YORK (GenomeWeb News) – Warnex today said that it has signed an agreement to serve as exclusive distributor of 10 of DeCode Genetics' tests in Canada.
Most of the DNA-based tests are for assessing risk of developing certain diseases. The tests will be sold by the Warnex Medical Laboratories division of the Laval, Quebec-based firm.
Among those included under the agreement are tests for assessing the risk of developing prostate cancer, myocardial infarction, atrial fibrillation, breast cancer, type 2 diabetes, and glaucoma. It also includes a test for clopidogrel dosing as well as three panels that address a wide range of cancers, cardiovascular diseases, and the DeCode Complete test, which analyzes risk factors for more than 45 common diseases and traits.
"Our test helps to meet the need for improved risk stratification and patient outcomes, and we believe that this alliance will make these benefits more widely available," DeCode Genetics CEO Kari Stefansson said in a statement.
Financial and other terms of the alliance were not disclosed.